S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Institutions are Buying up Procter & Gamble Shares, Should you?
NASDAQ:ABUS

Arbutus Biopharma - ABUS Stock Forecast, Price & News

$2.90
-0.11 (-3.65%)
(As of 02/1/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.90
$3.03
50-Day Range
$2.22
$3.01
52-Week Range
$1.85
$3.64
Volume
702,633 shs
Average Volume
811,291 shs
Market Capitalization
$434.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.50

Arbutus Biopharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
141.4% Upside
$7.00 Price Target
Short Interest
Healthy
3.14% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.60mentions of Arbutus Biopharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.46) to ($0.58) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.85 out of 5 stars

Medical Sector

806th out of 1,053 stocks

Pharmaceutical Preparations Industry

404th out of 519 stocks


ABUS stock logo

About Arbutus Biopharma (NASDAQ:ABUS) Stock

Arbutus Biopharma Corp. is a biopharmaceutical company. It engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.

Receive ABUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter.

ABUS Stock News Headlines

Arbutus Announces Resignation of Board Member
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
TRADING JABS
Arbutus to Participate in September Investor Conferences
See More Headlines
Receive ABUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter.

ABUS Company Calendar

Last Earnings
11/09/2022
Today
2/01/2023
Next Earnings (Estimated)
3/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ABUS
Employees
85
Year Founded
1992

Price Target and Rating

Average Stock Price Forecast
$7.00
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+124.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-76,250,000.00
Net Margins
-191.34%
Pretax Margin
-178.99%

Debt

Sales & Book Value

Annual Sales
$10.99 million
Book Value
$1.17 per share

Miscellaneous

Free Float
142,154,000
Market Cap
$434.86 million
Optionable
Optionable
Beta
2.13

Social Links


Key Executives

  • William H. Collier
    President, Chief Executive Officer & Director
  • Michael J. McElhaugh
    Chief Operating Officer
  • David C. Hastings
    Chief Financial & Accounting Officer
  • Michael J. Sofia
    Chief Scientific Officer
  • Elizabeth Howard
    Secretary, Chief Compliance Officer & EVP













ABUS Stock - Frequently Asked Questions

Should I buy or sell Arbutus Biopharma stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ABUS shares.
View ABUS analyst ratings
or view top-rated stocks.

What is Arbutus Biopharma's stock price forecast for 2023?

4 analysts have issued 12 month target prices for Arbutus Biopharma's stock. Their ABUS share price forecasts range from $5.00 to $9.00. On average, they expect the company's share price to reach $6.50 in the next year. This suggests a possible upside of 121.8% from the stock's current price.
View analysts price targets for ABUS
or view top-rated stocks among Wall Street analysts.

How have ABUS shares performed in 2023?

Arbutus Biopharma's stock was trading at $2.33 at the start of the year. Since then, ABUS shares have increased by 25.8% and is now trading at $2.93.
View the best growth stocks for 2023 here
.

When is Arbutus Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our ABUS earnings forecast
.

How were Arbutus Biopharma's earnings last quarter?

Arbutus Biopharma Co. (NASDAQ:ABUS) announced its earnings results on Wednesday, November, 9th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, hitting the consensus estimate of ($0.12). The biopharmaceutical company had revenue of $5.95 million for the quarter, compared to analyst estimates of $11.12 million. Arbutus Biopharma had a negative trailing twelve-month return on equity of 43.44% and a negative net margin of 191.34%.

What is Mark J. Murray's approval rating as Arbutus Biopharma's CEO?

6 employees have rated Arbutus Biopharma Chief Executive Officer Mark J. Murray on Glassdoor.com. Mark J. Murray has an approval rating of 22% among the company's employees. This puts Mark J. Murray in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Arbutus Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), GW Pharmaceuticals (GWPH), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), TherapeuticsMD (TXMD) and Novavax (NVAX).

What is Arbutus Biopharma's stock symbol?

Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."

Who are Arbutus Biopharma's major shareholders?

Arbutus Biopharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.55%), Clear Harbor Asset Management LLC (0.04%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Arbutus Biopharma?

Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arbutus Biopharma's stock price today?

One share of ABUS stock can currently be purchased for approximately $2.93.

How much money does Arbutus Biopharma make?

Arbutus Biopharma (NASDAQ:ABUS) has a market capitalization of $439.35 million and generates $10.99 million in revenue each year. The biopharmaceutical company earns $-76,250,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis.

How can I contact Arbutus Biopharma?

Arbutus Biopharma's mailing address is 701 VETERANS CIRCLE, WARMINSTER PA, 18974. The official website for the company is www.arbutusbio.com. The biopharmaceutical company can be reached via phone at (267) 469-0914, via email at ir@arbutusbio.com, or via fax at 604-419-3201.

This page (NASDAQ:ABUS) was last updated on 2/2/2023 by MarketBeat.com Staff